Related Experiment Video

Updated: Mar 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Hepatitis C genotype 3 disease

Sarah Kattakuzhy1, Rachel Levy2, Elana Rosenthal3

  • 1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA. skattakuzhy@ihv.umaryland.edu.

Hepatology International
|June 23, 2016
PubMed

Insights

Hepatitis C genotype 3 is difficult to treat, causing liver issues. New direct-acting antivirals show promise for eradicating this infection, though more research is needed.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C genotype 3 (GT-3) accounts for 30% of global HCV infections, with a high prevalence in South/Southeast Asia.
  • GT-3 infection is linked to increased risks of steatosis, fibrosis, and hepatocellular carcinoma, making it a priority for treatment.
  • Current direct-acting antiviral agents show variable efficacy against GT-3 compared to other genotypes.

Purpose of the Study:

  • To review the epidemiology and natural history of Hepatitis C genotype 3.
  • To summarize findings from Phase II and III clinical trials for GT-3 treatment options.
  • To discuss current and future therapeutic challenges in eradicating GT-3.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of clinical trial results for direct-acting antivirals in GT-3 patients.
  • Synthesis of current therapeutic landscape and future directions.

Main Results:

  • GT-3 infection presents unique challenges due to its association with significant liver disease progression.
  • Clinical trials are evaluating novel direct-acting antivirals with varying degrees of success in GT-3.
  • Eradication of GT-3 remains a complex therapeutic issue requiring further investigation.

Conclusions:

  • Hepatitis C genotype 3 represents a significant global health burden requiring effective and accessible treatment strategies.
  • Ongoing research and clinical trials are crucial for developing potent therapies against GT-3.
  • Addressing the specific challenges of GT-3 is essential for the overall goal of hepatitis C virus eradication.

Keywords:
Genotype-3Hepatitis CTreatment review

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
5